Læknablaðið - 01.03.2021, Side 17

L ÆK N A BL AÐIÐ 2021/107 129
R A N N S Ó K N
E N G L I S H S U M M A R Y
Katrín Júníana Lárusdóttir1
Hjalti Guðmundsson2
Árni Johnsen3
Martin Ingi Sigurðsson1,4
Tómas Guðbjartsson1,3
Ingibjörg Jóna Guðmundsdóttir1,2
1Faculty of Medicine, University of Iceland, 2Department
of Cardiology, 3Cardiothoracic surgery, 4Anesthesia and
Intensive Care, Landspitali University Hospital, Reykjavik,
Iceland
Correspondence: Ingibjörg J. Guðmundsdóttir,
ig@landspitali.is
Key words: Transcatheter aortic valve implantation,
aortic stenosis, indications, outcome, complications,
survival.
Indications and outcomes of TAVI (transcatheter aortic valve implantation) in Iceland
INTRODUCTION: Surgical aortic valve replacement (SAVR) has been the standard of
treatment for aortic stenosis but transcatheter aortic valve implantation (TAVI) is increasingly
used as treatment in Iceland and elsewhere. Our objective was to assess the outcome of TAVI
in Iceland, focusing on indications, complications and survival.
MATERIAL AND METHODS: This retrospective study included all TAVI-procedures performed
in Iceland between January 2012 and June 2020. Patient characteristics, outcome and
complications were registered, and overall estimated survival compared to an age and sex
matched Icelandic reference-population. The mean follow-up was 2.4 years.
RESULTS: Altogether 189 TAVI procedures (mean age 83±6 years, 41.8% females), were
performed, all with a self-expanding biological valve. Most patients (81.5%) had symptoms of
severe heart failure (NYHA-class III-IV) and median EuroSCORE-II was 4.9 (range: 0.9-32).
Echocardiography pre-TAVI showed a mean aortic-valve area of 0.67 cm2 and a max aortic-
valve gradient of 78 mmHg. One out of four patients (26.5%) needed permanent pacemaker
implantation following TAVI. Other complications were mostly vascular-related (13.8%) but
cardiac cardiac temponade and stroke occurred in 3.2 and 2.6% of cases, respectively and
severe paravalvular aortic valve regurgitation in 0.5% cases. Thirty-day mortality was 1.6%
(n=3) with one-year survival of 93.5% (95% CI: 89.8-97.3). Finally long-term survival survival of
TAVI-patients was similar to the matched reference population (p=0.23).
CONCLUSIONS: The outcome of TAVI-procedures in Iceland is good, especially regarding
30-day mortality and long-term survival that was comparable to a reference population.
Incidence of major complications was also low.
doi 10.17992/lbl.2021.03.625
Heimildir
1. Clavel MA, Pibarot P. A Decade of Revolutions in Calcific Aortic Stenosis. Cardiol Clin
2020; 38: xiii-xiv.
2. Danielsen R, Aspelund T, Harris TB, et al. The prevalence of aortic stenosis in the elderly in
Iceland and predictions for the coming decades: The AGES–Reykjavík study. Int J Cardiol
2014; 176: 916-22.
3. Carabello BA, Paulus WJ. Aortic stenosis. Lancet 2009; 373: 956-66.
4. Varadarajan P, Kapoor N, Bansal R, et al. Survival in elderly patients with severe aortic
stenosis is dramatically improved by aortic valve replacement: results from a cohort of 277
patients aged ≥80 years∗. Eur J Cardiothorac Surg 2006; 30: 722-7.
5. Viktorsson SA, Helgason D, Orrason AW, et al. Favorable Survival after Aortic Valve
Replacement Compared to the General Population. J Heart Valve Dis 2016; 25: 8-13.
6. Viktorsson SA, Vidisson KO, Gunnarsdottir AG, et al. Improved long-term outcome of sur-
gical AVR for AS: Results from a population-based cohort. J Cardiac Surg 2019; 34: 1235-42.
7. Iung B, Cachier AS, Baron G, et al. Decision-making in elderly patients with severe aortic
stenosis: why are so many denied surgery? Eur Heart J 2005; 26: 2714-20.
8. Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for
transcatheter aortic valve implantation per country: current estimates and future project-
ions. Eur Heart J 2018; 39: 2635-42.
9. Leon MB, Smith CR, Mack M, et al. Transcatheter Aortic-Valve Implantation for Aortic
Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med 2010; 363: 1597-607.
10. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus Surgical Aortic-Valve
Replacement in High-Risk Patients. N Engl J Med 2011; 364: 2187-98.
11. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter Aortic-Valve Replacement with a
Self-Expanding Prosthesis. N Engl J Med 2014; 370: 1790-8.
12. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve
Replacement in Intermediate-Risk Patients. N Engl J Med 2017; 376: 1321-31.
13. Thyregod HGH, Ihlemann N, Jørgensen TH, et al. Five-Year Clinical and
Echocardiographic Outcomes From the NOTION Randomized Clinical Trial in Patients at
Lower Surgical Risk. Circulation 2019; 139: 2714-23.
14. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-
Expanding Valve in Low-Risk Patients. N Engl J Med 2019; 380: 1706-15.
15. Rogers T, Thourani VH, Waksman R. Transcatheter Aortic Valve Replacement in
Intermediate- and Low-Risk Patients. J Am Heart Ass 2018; 7: e007147.
16. Makkar RR, Thourani VH, Mack MJ, et al. Five-Year Outcomes of Transcatheter or Surgical
Aortic-Valve Replacement. N Engl J Med 2020; 382: 799-809.
17. Guðmundsdóttir IJ. TAVI aðgerðir - Ósæðarlokuísetning með þræðingartækni. Reynslan á
Íslandi og alþjóðleg þróun. Læknablaðið 2017; 103: 221.
18. Nashef SAM, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012;
41: 734-45.
19. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions
for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2
consensus document (VARSC-2). Eur J Cardiothorac Surg 2012; 42: S45-S60.
20. University of California BU, and Max Planck Institute for Demographic Research
(Germany). Human Mortality Database.
21. Rodés-Cabau J, Ellenbogen KA, Krahn AD, et al. Management of Conduction
Disturbances Associated With Transcatheter Aortic Valve Replacement. J Am Coll Cardiol
2019; 74: 1086-106.
22. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of
valvular heart disease. Eur Heart J 2017; 38: 2739-91.
23. Forrest JK, Mangi AA, Popma JJ, et al. Early Outcomes With the Evolut PRO
Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC
Cardiovasc Interv 2018; 11: 160-8.
24. Hellhammer K, Piayda K, Afzal S, et al. The Latest Evolution of the Medtronic CoreValve
System in the Era of Transcatheter Aortic Valve Replacement: Matched Copmparison of
the Evolut PRO and Evolut R. JACC Cardiovasc Interv 2018; 11: 2314-22.
25. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in
Intermediate-Risk Patients. N Engl J Med 2016; 374: 1609-20.
26. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a
Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019; 380: 1695-705.